One of the recurring challenges in biotech patenting is that technologies which are difficult and highly iterative to develop — across antibodies, proteins, gene editing, gene therapy, and delivery systems — can appear deceptively straightforward once the solution is known.

That creates a familiar tension in obviousness analysis: once a target, scaffold, or platform is established, downstream modifications are often characterized as predictable optimization, even when the underlying biology is highly nonlinear and context-dependent in practice.

In areas like CRISPR systems, AAV gene therapy, and lipid nanoparticle delivery, small changes in guide design, capsid engineering, or formulation can produce disproportionate and often unintuitive effects on efficiency, specificity, tissue tropism, or toxicity. The scientific reality is frequently far less “predictable” than the legal framing suggests.

Overcoming an Obviousness Rejection

In that environment, overcoming an obviousness rejection depends heavily on whether the R&D process has been structured to generate the right kind of evidence, not just whether the invention ultimately works.

A few categories of data are particularly important.

1. Unexpected Results Relative to the Closest Prior Art

The strongest evidence is not improvement in isolation, but deviation from what the prior art would have predicted. This is most persuasive when results contradict established structure–function expectations or known optimization trends, making it difficult to characterize the invention as routine variation.

2. Non-Linear or Threshold Effects

Evidence that small changes produce disproportionate biological effects helps undermine “routine optimization” arguments. In gene editing and delivery systems, demonstrating sharp thresholds in activity, safety, or efficiency can be particularly powerful because it shows the system does not behave predictably along a continuum.

3. Failure of Generalization Across Prior Art Systems

Showing that known approaches do not transfer cleanly across contexts (cell types, payloads, tissues, or delivery environments) helps rebut the assumption that prior art solutions are broadly applicable. This is often critical in platform-heavy fields where modularity is used to argue obviousness.

4. Robust Head-to-Head Comparative Data

Well-controlled comparisons against the closest prior art (ex., across multiple endpoints) are often more persuasive than absolute performance metrics. They anchor the analysis in the legal standard: whether the claimed invention is meaningfully different from what came before, not simply whether it “works.”

Importantly, these categories of evidence should not be an afterthought in prosecution, but should be built into the R&D process itself.

In practice, that means:

• Designing experiments early that include closest prior art benchmarks, not just internal controls
• Intentionally probing parameter space to surface non-linear or threshold behavior, rather than only optimizing toward peak performance
• Testing cross-context generalizability (different cell types, payloads, delivery conditions) to identify where known systems break down
• Capturing “negative space” data—failures, drop-offs, and unexpected discontinuities—not just successful endpoints
• Structuring development iterations so that each meaningful modification has a corresponding comparative dataset tied back to a baseline

When these elements are embedded into development rather than reconstructed later, the resulting dataset does more than support patentability — it actively documents where predictability ends and true inventive contribution begins. Accomplishing this requires close collaboration between the R&D/scientific teams, and IP counsel, ideally creating a baseline “blueprint" of planned experiments embedded into any scientific discovery effort.

As biotech continues to move toward modular platforms and iterative engineering, the most important shift is this: non-obviousness is increasingly won or lost at the experimental design stage, not just the claim drafting stage, reinforcing that science drives the IP.